Company intelligence / Profile preview

Metabomed

Yavne, Center District, Israeltrial.medpath.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

Studies showed that a first-generation compound was active in patient-derived xenograft models with high ACSS2 expression, including as a single agent in colorectal and triple negative breast cancers, and in combination with platinum in gastric, ovarian, and non-small cell lung cancers[2]

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

MTB-9655

Phase 1

Indications: Advanced solid tumors

Beyond the preview

Go deeper on Metabomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metabomed.

Explore the full profile